A Mab A Case Study In Bioprocess Development [repack] Jun 2026

For subcutaneous delivery, the final drug product must be <2 mL volume. Mab-X is formulated at 150 mg/mL. Stability studies (4 weeks at 40°C) show that adding 0.02% polysorbate-80 prevents agitation-induced aggregation, but excess PS-80 causes visible particles. The optimized formulation is:

, which effectively separated the mAb from closely related variants that standard Protein A steps missed. PAT Integration: Implementing Process Analytical Technology A Mab A Case Study In Bioprocess Development

Using tangential flow filtration (TFF) with 30 kDa cassettes, the team concentrates Mab-X from 2 mg/mL to 120 mg/mL. At 100 mg/mL, viscosity reaches 25 cP, causing high pump shear and membrane fouling. For subcutaneous delivery, the final drug product must

The process begins by identifying the antibody's CQAs—physical, chemical, biological, or microbiological properties that must be within an appropriate limit to ensure safety and efficacy. The optimized formulation is: , which effectively separated

The success of "A Mab" was not in any single step, but in the systematic, risk-based integration of upstream and downstream unit operations — a blueprint for modern bioprocess development.